<DOC>
	<DOCNO>NCT02561962</DOCNO>
	<brief_summary>This first human phase 1 multicenter open label study subject relapse refractory multiple myeloma .</brief_summary>
	<brief_title>A Phase 1 Study Subjects With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>This first human phase 1 multicenter open label study evaluate safety tolerability AMG 224 subject relapse refractory multiple myeloma . The study conduct 2 part . Part 1 dose-exploration part 2 dose-expansion . Study medication administer every 3 week IV .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Pathologically document , multiple myeloma relapse refractory progressive disease least 3 line therapy multiple myeloma . Prior therapeutic treatment regimen must include proteasome inhibitor ( e.g . bortezomib ) immunomodulatory drug ( e.g . lenalidomide ) . Willing able undergo bone marrow aspirate per protocol ( without bone marrow biopsy per institutional guideline ) . Measurable disease per IMWG response criterion Hematological function , follow , without transfusion support : Absolute neutrophil count ≥ 1.0 X 109/L , Platelet count ≥ 75 X 109/L ( patient &lt; 50 % bone marrow nucleate cell plasma cell ) ≥ 50 X 109/L ( patient ≥ 50 % bone marrow nucleate cell plasma cell ) without transfusion growth factor support Hemoglobin &gt; 8 g/dL ( &gt; 80 g/L ) Adequate renal hepatic function Left ventricular ejection fraction ( LVEF ) &gt; 50 % Currently receive treatment another investigational device drug study , less 28 day since end treatment another investigational device drug study Antitumor therapy ( chemotherapy , antibody therapy , molecular target therapy , investigational agent ) within 28 day prior study day 1 Multiple myeloma IgM subtype Glucocorticoid therapy ( prednisone &gt; 30 mg/day equivalent ) within 7 day prior study day Autologous stem cell transplant le 90 day prior study day 1 POEM syndrome , Plasma cell leukemia , Waldenstrom 's macroglobulinemia Amyloidosis Myocardial infarction within 6 month study day 1 , symptomatic congestive heart failure ( New York Heart Association &gt; class II ) A baseline ECG QTcF &gt; 470 msec</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed Multiple Myeloma</keyword>
	<keyword>Refractory Multiple Myeloma</keyword>
</DOC>